Kalaris Therapeutics Inc

Direct answer

Kalaris Therapeutics Inc is publicly traded on NASDAQ under the ticker KLRS.

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.

Can you invest in Kalaris Therapeutics Inc?

Yes. Kalaris Therapeutics Inc is publicly traded on NASDAQ under the ticker KLRS.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Kalaris Therapeutics Inc

Detailed equity research is provided by MarketSnap.